Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Creabilis SA160 enrolled

Overview

The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

160

Conditions

Psoriasis Vulgaris

Interventions

CT327 0.05%DRUG

0.05% CT327 (w/w) ointment

CT327 0.1%DRUG

0.1% CT327 (w/w) ointment

CT327 0.5%DRUG

0.5% CT327 (w/w) ointment

Placebo

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female subjects aged at least 18 years. * Stable psoriasis vulgaris Exclusion Criteria: * Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.

Locations (13)

Unnamed facility

Hotsprings, Arkansas, United States

Unnamed facility

San Ramon, California, United States

Unnamed facility

Bay City, Michigan, United States

Unnamed facility

Fridley, Minnesota, United States

Outcomes

Primary Outcomes

Efficacy of CT327 ointment (0.05%, 0.1% and 0.5% w/w) compared with placebo ointment.

Time frame: Week 8

Secondary Outcomes

Local and systemic toleration

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.